The FDA Sentinel Real World Evidence Data Enterprise (RWE‐DE)

Documenti analoghi

• Transparency, reproducibility, and replicability of pharmacoepidemiology studies in a distributed network environment
  di: Ashish Rai, et al.
  Pubblicazione: (2024)
• A Plasmode Simulation‐Based Bias Analysis for Residual Confounding by Unmeasured Variables Leveraging Information‐Rich Subsets
  di: Rishi J. Desai, et al.
  Pubblicazione: (2026)
• Exposure to Valsartan Products Containing Nitrosamine Impurities in the United States, Canada, and Denmark
  di: Efe Eworuke, et al.
  Pubblicazione: (2024)
• PMDA Perspective on RWD/RWE Utilization for Regulatory Purposes Including Assessment on the Impacts of Regulatory Actions and Safety Risk of a Drug at Postmarketing Stage
  di: Kazuhiro Kajiyama, et al.
  Pubblicazione: (2024)
• Emulation of randomized trials of direct oral anticoagulants with claims data and implications for new Factor XI inhibitors
  di: Shirley V. Wang, et al.
  Pubblicazione: (2024)